Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome
Status:
Recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of
complex regional pain syndrome (CRPS). Study participants will be randomly assigned to
receive either LDN or placebo for a period of several weeks. During this period participants
will be asked to come to several visits, which will include sensory testing, physical
assessments, and questionnaires.